Breaking News

GenScript ProBio, Curocell Partner on Next-Gen CAR-T Therapy

Alliance aims to strengthen cooperation on development, production, and clinical trials of viral vectors for CAR-T therapy R&D.

GenScript ProBio, a CDMO and specialized CAR-T therapy firm, and Curocell, entered into a strategic partnership MOU for the production of viral vectors necessary for the development of next generation CAR-T therapies. The partnership will broaden the strategic cooperation between the two companies to encompass the entire project, including the development, production, and clinical trials of viral vectors for CAR-T therapy research and development. Viral vectors are vehicles for drug delive...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters